Position in AVXL
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$104,853
-$21,366 QoQ
Shares Held
40,484
-1.5% QoQ
Ownership
0.044%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#64
of 179 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AVXL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Snowden Capital Advisors LLC holds $12,669,600 across 24 Biotechnology names. AVXL ranks #23 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,230 | $2,101,167 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,732 | $1,703,511 | |
| 3 | ARGX |
Argenx SE
|
1,311 | $1,216,306 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
1,952 | $1,048,126 | |
| 5 | INSM |
INSMED Inc
|
7,262 | $774,274 | |
| 6 | IDYA |
IDEAYA Biosciences, Inc.
|
17,281 | $644,062 | |
| 7 | QURE |
uniQure N.V.
|
10,874 | $500,856 | |
| 8 | ASND |
Ascendis Pharma A/S
|
1,583 | $422,217 |
All Filings in AVXL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $104,853 | 40,484 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $126,219 | 41,114 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $152,072 | 42,717 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||